Marimastat oral matrix metalloproteinase inhibitor data

BBIOY reported results of several open label, 28-day Phase II studies and a meta-analysis of the trials. As presented at the Congress of the European Society for Medical Oncology in Vienna, the data

Read the full 334 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE